Cmax differences represent differences in the magnitude geometry of the maximum plasma concentration within a pharmacokinetic trajectory. Cmax is the highest measured or modeled concentration reached during the observed concentration-time profile, and its magnitude emerges from the interaction between systemic input and disposition rather than from absorption alone. The ascending phase reflects drug entering the systemic compartment, while distribution and elimination operate concurrently and progressively oppose accumulation within the measured compartment. A more concentrated systemic input can increase the steepness and magnitude of the rising phase, whereas a more dispersed input can produce a broader concentration trajectory. Absorption extent also contributes because it determines the total amount entering systemic circulation, but extent and rate are distinct PK dimensions. Distribution overlap can further modify central concentration by transferring drug between central and peripheral spaces while absorption is still occurring. Consequently, Cmax is a composite descriptor of peak-magnitude geometry. It should be interpreted strictly as a PK concentration parameter and not as a measure of clinical effect intensity. Mechanistic comparisons between formulations therefore focus on how their input and disposition characteristics shape the height of the concentration trajectory. This framework is relevant when comparing viagra vs sildenafil as pharmacokinetic systems.
Absorption rate determines how rapidly systemic concentration is formed during the rising phase of a concentration-time profile. When input is concentrated over a relatively short interval, plasma concentration can increase rapidly, producing a steep ascending trajectory that may contribute to a higher concentration maximum. When systemic input is spread over a longer interval, the rising phase can become flatter and more prolonged. The effect of absorption rate on Cmax is nevertheless conditional on the simultaneous action of distribution and elimination. Incoming drug may move from the central compartment into peripheral spaces while absorption continues, while elimination removes drug throughout the trajectory. Thus, the observed peak magnitude represents the net accumulation remaining in the measured compartment at the point of maximum concentration. Absorption rate should also be distinguished from absorption extent. Rate describes how systemic input is distributed across time, whereas extent describes the total amount entering systemic circulation. A change in rate can therefore reshape the peak even when total input is conceptually similar, while a change in extent can alter the amount available to form the peak. The mechanistic relationship between input timing, rising-phase steepness, and peak concentration is developed further in absorption.
Absorption extent describes the total amount of drug entering systemic circulation from the absorption process and therefore contributes directly to the overall exposure magnitude available to generate a concentration peak. Greater systemic input can increase the concentration trajectory when disposition characteristics remain otherwise comparable, while reduced systemic input can lower the available amount. Cmax, however, is not identical to total exposure. Exposure integrates concentration over time, whereas Cmax represents the maximum point reached by the concentration trajectory. The relationship between extent and Cmax therefore depends on how the systemic input is distributed temporally and how disposition processes operate during the rising phase. Two input functions can have similar total systemic amounts but different rates of entry, producing different peak magnitudes. Conversely, a change in systemic input amount can influence Cmax while producing a different proportional change in total exposure depending on the underlying PK model. Distribution volume, compartmental transfer, and elimination also affect how much of the absorbed amount remains represented in the measured compartment when the maximum occurs. Mechanistic PK comparison therefore separates absorption extent from peak magnitude while recognizing their interaction. This distinction is central to interpreting pk comparison without treating Cmax as a direct proxy for any clinical effect.
Dissolution and gastric emptying operate upstream of systemic absorption and can modify the temporal geometry of drug availability. Dissolution determines how rapidly a solid drug material becomes available in a form suitable for subsequent absorption, while disintegration can influence the physical transition preceding dissolution. Gastric emptying then controls the timing with which dissolved material moves from the stomach into the intestinal region where substantial systemic absorption can occur. These processes therefore influence when and how rapidly systemic input begins to develop. Earlier or more concentrated availability can contribute to a steeper rising concentration trajectory, while delayed or dispersed availability can broaden the input profile. Their effects on Cmax are mediated through the resulting systemic input rather than representing independent peak-generating mechanisms. The eventual concentration maximum also depends on absorption extent, distribution, and elimination, all of which operate downstream or concurrently. Consequently, a change in dissolution timing does not automatically translate into a proportional change in Cmax, because the input geometry is transformed by subsequent PK processes. Gastric emptying similarly affects the temporal delivery of absorbable material rather than directly determining peak concentration. These upstream determinants are therefore best interpreted as components of absorption geometry, as described in absorption.
Distribution overlaps with absorption during the rising phase because newly absorbed drug enters the central systemic compartment while transfer toward peripheral compartments can occur simultaneously. In a compartmental representation, central concentration therefore reflects both incoming systemic input and redistribution away from or back toward the measured compartment. Early transfer can influence the amount of drug represented centrally at each point in time, thereby modifying the height and shape of the concentration trajectory. A larger or faster distribution process can reduce the fraction of incoming drug remaining in the central compartment during part of the rising phase, while slower equilibration can produce a different central accumulation pattern. These effects interact with absorption rate and extent rather than acting independently. The resulting Cmax is consequently determined by the concentration remaining in the measured compartment when systemic input and disposition reach the balance associated with the maximum. Distribution volume also affects the relationship between amount and concentration, meaning that the same systemic amount can correspond to different concentration magnitudes under different distribution characteristics. Cmax should therefore be interpreted as a concentration outcome of the complete PK system rather than a direct measurement of absorbed amount. The central and peripheral processes underlying this geometry are described in distribution.
Cmax and Tmax represent two complementary coordinates of the same concentration peak. Cmax describes the vertical dimension of the trajectory, identifying the maximum concentration reached, while Tmax describes the horizontal dimension, identifying when that maximum occurs. Both emerge from the same underlying input–disposition balance, but they summarize different geometric properties. Absorption extent, absorption rate, distribution, and elimination can influence peak magnitude, while the timing of dissolution, gastric emptying, systemic input, distribution transfer, and elimination can influence the location of the maximum. A change in one upstream process can therefore affect both Cmax and Tmax, but the magnitude of those changes need not be proportional. For example, concentrating systemic input earlier can steepen the rising phase and potentially alter peak magnitude while also shifting peak timing. Increasing total systemic input can increase Cmax without necessarily producing the same directional change in Tmax. Thus, Cmax cannot be treated as a timing parameter, and Tmax cannot be treated as a magnitude parameter. Their joint interpretation provides a two-dimensional description of peak formation. The distinction between the vertical and horizontal components of the peak is central to mechanistic interpretation of Tmax and Cmax without assigning either parameter a clinical-effect meaning.
Peak-effect variability, when interpreted strictly as peak PK variability, describes differences in the formation and magnitude of the concentration maximum rather than differences in subjective effect. Several mechanistic sources can contribute. Dissolution variability can alter the timing and rate at which material becomes available for absorption. Gastric-emptying variability can shift the temporal delivery of that material into the absorptive region. Absorption-rate variability can change the steepness of the rising concentration phase, while absorption-extent variability can alter the total systemic amount available to form the peak. Distribution variability can modify central-to-peripheral transfer during the same interval, changing how much of the incoming drug remains represented in the measured compartment. These determinants can interact, producing a composite change in peak height, peak width, and peak timing. Because Cmax is an emergent property of the concentration-time trajectory, variability in any upstream or concurrent PK process can propagate into peak-magnitude variability. The resulting variation should therefore be described in terms of systemic input geometry, compartmental distribution, and disposition rather than subjective effect intensity. This framework distinguishes peak PK formation from clinical interpretation and places the relevant sources of variability within the broader context of pk variability.
Absorption rate describes the temporal speed at which drug enters the systemic circulation during the input phase. In a concentration-time profile, this rate contributes to the steepness of the rising phase because more concentrated systemic input produces a faster increase in plasma concentration. A slower or more dispersed input produces a broader and less steep ascending trajectory. The observed slope is not a pure measurement of absorption because distribution and elimination occur simultaneously. As drug enters the central compartment, some can transfer into peripheral spaces, while elimination removes drug from the system. The measured rising-phase concentration therefore reflects the net result of input and disposition. Absorption rate should also be distinguished from absorption extent. Rate describes when systemic input occurs, whereas extent describes how much drug ultimately enters systemic circulation. These dimensions can change independently in a mechanistic model and can therefore produce different effects on peak formation. A faster rate can concentrate systemic input and increase the instantaneous accumulation available to generate Cmax, while total input may remain conceptually unchanged. The relevant geometric framework is developed in absorption.
The relationship between absorption rate and Cmax follows from the amount of drug accumulating in the measured compartment before disposition offsets further concentration increase. A relatively rapid input can produce a steep rising phase and a larger instantaneous concentration when distribution and elimination do not fully offset the incoming drug. A slower input can allow disposition processes to operate over a longer interval during systemic entry, potentially reducing the concentration maximum. However, this relationship is not a simple one-variable rule. Distribution volume, central-to-peripheral transfer, elimination, and the shape of the input function all influence the resulting peak. A change in absorption rate can therefore alter Cmax differently depending on the surrounding PK parameters. Similarly, two systems with different absorption rates can produce comparable peak magnitudes if compensating disposition characteristics are present. Cmax is consequently an emergent peak-magnitude parameter rather than a direct measurement of absorption rate. The mechanistic interpretation is the relationship between the temporal concentration of systemic input and the resulting height of the concentration trajectory. This distinction is central to understanding Cmax.
| Absorption Domain | Mechanistic Determinant | Link |
|---|---|---|
| Absorption Rate | Rising-phase steepness. | absorption |
| Rate → Cmax | Peak-magnitude formation. | cmax |
Absorption extent represents the total amount of drug that reaches systemic circulation from the absorption process. It is therefore a determinant of the overall amount available to generate the concentration-time trajectory and contributes to exposure magnitude. In a simplified system with otherwise unchanged disposition, increasing systemic input can increase the amount present in the body and can consequently increase concentration values, including the maximum. In a mechanistic PK comparison, however, absorption extent must be separated from absorption rate. Extent concerns the amount entering systemic circulation, whereas rate concerns the temporal pattern of that entry. The same total systemic input can be distributed rapidly or slowly, producing different concentration-time shapes and potentially different Cmax values. Exposure magnitude also differs conceptually from Cmax because exposure integrates concentration over time, while Cmax identifies a single maximum point. Distribution volume, compartmental transfer, and clearance can further modify the concentration generated by a given systemic amount. Therefore, absorption extent provides an important input determinant but does not uniquely determine peak magnitude. This distinction is useful when interpreting comparative PK parameters in pk comparison.
The extent-to-Cmax relationship depends on how much systemic drug is available and how that amount is temporally distributed before the peak occurs. If the systemic input amount increases while absorption rate and disposition remain otherwise comparable, the concentration trajectory can be shifted upward, producing a larger peak magnitude. The proportionality is not necessarily exact because distribution and elimination can respond to the changed concentration trajectory within the PK model, and because the timing of input affects how much drug remains in the measured compartment at the maximum. A larger absorption extent can therefore increase exposure without producing an identical proportional increase in Cmax. Conversely, two profiles can reach different Cmax values despite similar total exposure if their input functions and disposition geometry differ. Cmax is thus best viewed as a local maximum of the concentration trajectory, while absorption extent is a system-level input quantity. The relationship becomes especially important when comparing formulations or input systems because differences in systemic availability can propagate into peak magnitude while remaining mechanistically distinct from absorption rate. The peak parameter itself is described in Cmax.
| Extent Domain | Mechanistic Determinant | Link |
|---|---|---|
| Absorption Extent | Exposure magnitude. | pk comparison |
| Extent → Cmax | Peak magnitude. | cmax |
Dissolution is an upstream process that determines how rapidly solid drug material becomes available in a dissolved form for subsequent absorption. In PK geometry, the timing of dissolution can shape the onset and temporal concentration of systemic input. More rapid availability can allow absorption to begin earlier or become concentrated over a shorter interval, while slower availability can spread input over a longer interval. The resulting effect on Cmax is mediated through the downstream absorption function rather than arising directly from dissolution itself. The amount available for absorption also matters, because dissolution timing and dissolution extent can influence the amount entering the next stage of the input process. Once absorption begins, distribution and elimination operate concurrently, transforming the upstream availability profile into the observed plasma concentration trajectory. Therefore, a difference in dissolution timing can modify peak magnitude by changing the temporal geometry of systemic input, but the magnitude of the change depends on absorption rate, absorption extent, distribution, and clearance. Dissolution should consequently be treated as one component of the complete input pathway. Its relationship to early systemic exposure is described within the mechanistic framework of absorption.
Gastric emptying determines the timing with which dissolved drug moves from the stomach toward the intestinal region where systemic absorption can occur. As an upstream timing process, it can shift the delivery of available drug and therefore modify the temporal pattern of systemic input. Earlier delivery can concentrate absorptive input into an earlier portion of the concentration-time trajectory, while delayed or more dispersed delivery can broaden the rising phase. The eventual Cmax depends on how this altered input interacts with absorption rate and extent, distribution, and elimination. Gastric emptying therefore does not directly specify the height of the concentration maximum. Instead, it modifies the timing and shape of the input function that subsequently generates the plasma concentration profile. If input is redistributed across time, the same total systemic amount can produce a different peak magnitude because disposition operates continuously during absorption. This illustrates why upstream timing parameters should be separated from downstream concentration parameters. Gastric-emptying effects are consequently interpreted as modifications of systemic input geometry rather than direct changes in Cmax itself. The broader sequence from upstream availability through systemic absorption is represented in absorption.
| Upstream Domain | Mechanistic Determinant | Link |
|---|---|---|
| Dissolution | Availability for absorption. | absorption |
| Gastric Emptying | Timing of systemic entry. | absorption |
Early distribution occurs while absorption continues to deliver drug into the central systemic compartment. Newly absorbed drug can therefore move between central and peripheral spaces before the concentration maximum has been reached. In a compartmental model, this transfer changes the amount remaining in the measured central compartment at each point in time. Faster transfer toward peripheral spaces can reduce central accumulation during part of the rising phase, while slower equilibration can preserve more of the incoming drug within the central compartment. Distribution volume also influences the relationship between drug amount and measured concentration, so a given systemic amount does not necessarily correspond to the same plasma concentration under different distribution geometries. These effects overlap with absorption rate and extent, creating an integrated concentration trajectory. Consequently, early distribution is not a separate post-absorption event that begins only after Cmax formation. It is part of the simultaneous disposition process shaping the rising phase. The mechanistic interpretation is therefore based on central-to-peripheral transfer, peripheral-to-central return, equilibration, and their relative rates compared with systemic input. These processes are described in greater detail in distribution.
Distribution can modify Cmax because the maximum concentration reflects the amount of drug represented in the measured compartment at the point where the concentration trajectory reaches its highest value. While absorption adds drug to the central compartment, distribution can move part of that amount into peripheral spaces. If transfer is substantial during the rising phase, central concentration may accumulate differently than it would under a single-compartment representation. Conversely, slower distribution can produce a different concentration profile by allowing more incoming drug to remain centrally represented for a given interval. Redistribution and equilibration can subsequently return drug toward the central compartment, further influencing the trajectory around and after the peak. The magnitude of the effect depends on distribution volume, transfer coefficients, and the relative timing of absorption and elimination. Thus, distribution does not simply raise or lower Cmax through a universal mechanism; its influence depends on the complete PK configuration. Cmax is consequently a property of the concentration-time trajectory rather than a direct measure of total systemic drug amount. The resulting peak-magnitude geometry is represented by Cmax.
| Distribution Domain | Mechanistic Determinant | Link |
|---|---|---|
| Early Distribution | Redistribution during rising-phase. | distribution |
| Distribution → Cmax | Peak-magnitude modification. | cmax |
Cmax and Tmax are complementary descriptors of a single concentration maximum. Cmax identifies the vertical height of the peak, whereas Tmax identifies its horizontal time coordinate. Both are generated by the same input–disposition trajectory, but they describe different dimensions of peak geometry. Absorption extent and distribution characteristics can strongly influence concentration magnitude, while absorption rate and input timing can influence how rapidly the trajectory reaches its maximum. Dissolution and gastric emptying can modify the timing and concentration of upstream input, while distribution and elimination operate simultaneously. Consequently, a change in one PK determinant can modify both Cmax and Tmax without producing the same proportional change in each. A temporally concentrated input may alter peak magnitude and peak timing together, while a change in total systemic input may primarily shift the vertical dimension. Likewise, a distribution change can modify concentration magnitude and alter the timing at which the concentration maximum is reached. The parameters therefore should not be collapsed into a single measure. Mechanistically, Cmax describes how high the trajectory rises and Tmax describes when the maximum occurs. This distinction is fundamental to interpretation of Cmax.
The input–disposition balance shapes both peak magnitude and peak timing because concentration rises only while systemic input exceeds the combined processes reducing concentration in the measured compartment. Increasing or concentrating input can increase the amount accumulating centrally and thereby affect Cmax, while also changing the time at which the net rate of concentration change reaches zero. Distribution can simultaneously remove drug from the central compartment, and elimination continuously contributes to concentration decline. The resulting peak is therefore the point at which these processes produce a maximum in the concentration trajectory. A change in systemic input may shift this point vertically, horizontally, or along both dimensions depending on the specific PK geometry. Cmax should thus be interpreted as the magnitude coordinate generated by the complete trajectory, while Tmax represents the timing coordinate. Neither parameter alone identifies the underlying mechanism. Their joint behavior can instead be used to distinguish changes in input magnitude, input timing, distribution, and disposition. The timing dimension of this same peak geometry is examined in Tmax.
Dissolution variability can produce variability in peak PK formation by changing the timing and temporal availability of drug for absorption. If dissolution occurs over a shorter or longer interval, the downstream systemic input function can become more concentrated or more dispersed. This modifies the rising-phase concentration geometry and can alter the amount of drug accumulating in the measured compartment before disposition offsets further increase. Dissolution variability is therefore an upstream source of variation in Cmax rather than a direct determinant of peak concentration. Its contribution is transformed by subsequent absorption, distribution, and elimination. The same dissolution difference can produce different peak-magnitude consequences under different downstream PK configurations because absorption rate and distribution characteristics determine how available material becomes systemic concentration. Dissolution extent can also influence how much material becomes available for absorption, adding an amount dimension to the timing effect. Mechanistically, the relevant variables are availability, temporal input, and the resulting concentration trajectory. Peak variability should therefore be interpreted as variability in PK peak formation rather than variability in subjective effect. These upstream and downstream interactions are included within the broader framework of pk variability.
Gastric-emptying variability can alter the timing with which dissolved drug reaches the intestinal absorptive region and therefore modify the temporal pattern of systemic input. Earlier delivery can concentrate absorption into an earlier interval, whereas delayed or more dispersed delivery can extend the input phase. Because absorption, distribution, and elimination continue simultaneously, the resulting change in Cmax depends on the complete input–disposition system. A shift in emptying timing can therefore modify peak magnitude even when the total amount eventually absorbed remains conceptually similar. The mechanism is temporal redistribution of systemic input rather than a direct effect of gastric emptying on plasma concentration. Variability in emptying can also interact with dissolution variability, producing different availability profiles before absorption begins. The downstream absorption rate then determines how strongly these upstream timing differences are expressed in the rising concentration phase. Distribution can further modify how much of that incoming drug remains in the measured central compartment at peak formation. Thus, gastric-emptying variability contributes to peak PK variability through changes in input geometry. This mechanism belongs within the broader framework of pk variability.
Absorption-rate variability changes the steepness and temporal concentration of systemic input, while distribution variability changes how incoming drug is partitioned between central and peripheral spaces during the same rising phase. A faster effective absorption process can concentrate input and alter peak magnitude, whereas a slower process can spread input across a longer interval. Distribution variability can simultaneously modify central accumulation through differences in transfer rates, distribution volume, and equilibration. The resulting Cmax is therefore influenced by the interaction between input geometry and disposition rather than by either component alone. Peak-magnitude variability can arise even when total systemic input is similar if the temporal distribution of that input or the distribution geometry differs. Conversely, similar peak magnitudes can arise from different combinations of rate, extent, and disposition parameters. The mechanistic endpoint is variation in the height and shape of the PK concentration maximum, not variation in subjective effect. Because these processes overlap, interpretation of peak variability requires separating upstream input differences from central and peripheral disposition differences. The resulting variability can be conceptualized through rising-phase slope, peak height, and peak timing. These relationships are captured within pk variability.
| Variability Domain | Mechanistic Determinant | Link |
|---|---|---|
| Dissolution Variability | Availability variability. | pk variability |
| Emptying Variability | Timing variability. | pk variability |
| Rate Variability | Rising-phase variability. | pk variability |
| Distribution Variability | Equilibration variability. | pk variability |
Cmax is the maximum measured or modeled plasma concentration reached within a concentration-time profile. It represents the vertical coordinate of the concentration peak and is therefore a parameter of peak-magnitude geometry. Mechanistically, Cmax emerges from the balance between systemic input and disposition. Absorption supplies drug to the systemic compartment, while distribution transfers drug between compartments and elimination removes drug from the system. The resulting concentration rises until these processes produce the maximum concentration, after which the trajectory declines. Cmax is distinct from total exposure because exposure integrates concentration over time, whereas Cmax represents a single maximum point. It is also distinct from Tmax, which identifies the time coordinate of that maximum. Changes in absorption rate, absorption extent, dissolution, gastric emptying, distribution, and elimination can therefore alter Cmax through different mechanisms. Cmax should be interpreted strictly as a PK concentration parameter and not as a measure of clinical effect intensity or subjective response.
Absorption rate shapes Cmax by controlling how rapidly systemic input develops during the rising phase of the concentration-time profile. A relatively concentrated input can produce a steeper increase in plasma concentration, allowing more drug to accumulate in the measured compartment before disposition offsets the incoming amount. A slower or more dispersed input can produce a broader rising phase, giving distribution and elimination more time to operate while absorption continues. The resulting peak magnitude therefore depends on the temporal concentration of systemic input. Absorption rate does not act independently, however. Distribution volume, central-to-peripheral transfer, elimination, and absorption extent all influence the concentration reached at the maximum. Consequently, a faster absorption rate does not guarantee a proportionally higher Cmax under every PK configuration. Two systems with different absorption rates can produce similar peak magnitudes if other parameters compensate, while similar rates can produce different Cmax values when disposition differs. Mechanistically, Cmax reflects the integrated input–disposition trajectory rather than absorption rate alone.
Absorption extent determines the total amount of drug entering systemic circulation and therefore establishes the amount available to generate the concentration-time profile. When other PK characteristics remain comparable, a larger systemic input can increase concentration and contribute to a larger Cmax. The relationship is not necessarily proportional because Cmax is a local maximum that also depends on the temporal pattern of absorption and on concurrent distribution and elimination. Absorption extent should therefore be distinguished from absorption rate. Two input functions can deliver similar total systemic amounts while producing different peak magnitudes if one delivers the amount rapidly and the other distributes it over a longer interval. Conversely, a change in total systemic input can alter exposure and Cmax while producing a smaller or different change in Tmax. Distribution volume also affects the concentration associated with a given amount of drug. Thus, absorption extent is an important determinant of peak formation, but Cmax remains an emergent parameter of the complete PK system rather than a direct measurement of absorbed amount.
Distribution overlaps with absorption when newly absorbed drug enters the central compartment while transfer toward peripheral compartments is already occurring. During this period, the measured central concentration reflects both incoming systemic input and movement of drug between compartments. Faster transfer into peripheral spaces can alter central accumulation during the rising phase, while slower equilibration can preserve a different central concentration trajectory. Distribution volume also affects the relationship between drug amount and concentration, so identical systemic amounts can produce different plasma concentrations under different distribution geometries. These processes influence Cmax because the peak is determined by the concentration remaining in the measured compartment when the overall trajectory reaches its maximum. Redistribution and return transfer can further shape the profile around and after the peak. Distribution therefore does not act as a universal upward or downward determinant of Cmax; its contribution depends on transfer rates, volume, input timing, and elimination. Mechanistically, Cmax is the result of overlapping absorption and disposition processes rather than absorption considered in isolation.
Cmax and Tmax describe two complementary coordinates of the same concentration maximum. Cmax identifies how high the concentration trajectory rises, while Tmax identifies when that maximum occurs. Both are generated by the balance between systemic input and disposition, but they capture different aspects of the resulting geometry. Absorption extent, absorption rate, distribution, and elimination can influence peak magnitude, while dissolution timing, gastric emptying, input rate, distribution transfer, and elimination can influence peak timing. A single PK change can therefore modify both Cmax and Tmax, but the changes do not need to be proportional. A more concentrated input may alter the height and timing of the peak simultaneously, whereas a change in systemic amount may primarily affect peak magnitude. Conversely, a timing shift can change Tmax with a comparatively smaller change in Cmax. The parameters should therefore not be treated as interchangeable. Cmax is the vertical peak coordinate, and Tmax is the horizontal peak coordinate. Their joint interpretation describes peak formation without assigning either parameter a clinical-effect meaning.
Peak-effect variability, interpreted strictly as peak PK variability, arises from differences in the processes that construct the concentration maximum. Dissolution variability can change when and how rapidly material becomes available for absorption. Gastric-emptying variability can shift the timing of delivery into the absorptive region. Absorption-rate variability can alter the steepness of the rising phase, while absorption-extent variability changes the total systemic amount available to generate the concentration trajectory. Distribution variability can modify central-to-peripheral transfer and equilibration while absorption continues. Elimination operates concurrently and can further influence the amount remaining in the measured compartment at peak formation. These processes can interact, so variability in Cmax may reflect several contributing mechanisms rather than a single determinant. Similar peak magnitudes can arise from different combinations of rate, extent, distribution, and elimination, while similar input amounts can produce different peaks when their temporal geometry differs. The mechanistic interpretation is therefore variability in peak concentration formation, not variability in subjective effect intensity or clinical response.